The Recombinant Cynomolgus Glypican-3/GPC3 Protein is a high-quality recombinant protein produced for advanced research applications in molecular biology and biotechnology. This protein serves as a critical reagent in various experimental contexts, including functional studies, binding assays, and therapeutic development programs, providing researchers with a standardized and reliable tool for investigating protein function and interactions.
This product (SKU: RPCB1728) is produced using HEK293 cells and features a C-His tag for convenient detection and purification. The protein exhibits a calculated molecular weight of 61.8 kDa with an observed molecular weight of 42, 70-135 kDa under denaturing conditions, achieving ≥ 95 % as determined by Tris-Bis PAGE;≥ 95 % as determined by HPLC., ensuring exceptional quality and consistency for research applications.
High quality, high purity and low endotoxin recombinant Recombinant Cynomolgus Glypican-3/GPC3 Protein (RPCB1728), tested reactivity in HEK293 cells and has been validated in SDS-PAGE.100% guaranteed.
Endotoxin:
< 1 EU/μg of the protein by LAL method.
Purity:
≥ 95 % as determined by Tris-Bis PAGE;≥ 95 % as determined by HPLC.
Reconstitution:
Centrifuge the tube before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.
Storage:
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.
Glypican-3 is a protein,which is encoded by the GPC3 gene in humans.The protein core of GPC3 consists of two subunits, where the N-terminal subunit has a size of ~40 kDa and the C-terminal subunit is ~30 kDa.Glypican 3 is a potential therapeutic target for treating liver cancer and other cancers. Several therapeutic anti-GPC3 antibodies have been developed.
Recombinant Cynomolgus Glypican-3/GPC3 Protein was determined by Tris-Bis PAGE under reducing conditions.
The purity of Cynomolgus GPC3 is greater than 95% as determined by SEC-HPLC.
